BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based
medical device company redefining interventional radiation safety, today announced that
Rob Williamson has been appointed Chief Revenue OFicer (CRO), eFective March 1.
Williamson previously served on Rampart’s Board of Directors.
Williamson brings more than 25 years of medical device leadership experience, including
senior commercial roles at Medtronic, Covidien, ev3, FoxHollow, and Bard. Most recently,
he served as Vice President of Sales at Shockwave Medical, where he built and led a 300+
person field organization and helped scale the company to more than $500 million in
annual revenue.
As CRO, Williamson will lead Rampart’s U.S. Sales organization, focusing on revenue
growth, field execution, and team expansion. Brian Chambless continues as Chief
Commercial Officer, leading Rampart’s global commercial strategy.
“Rampart is entering an important stage of development as we see signs of change in the
standard of care for radiation and orthopedic protection in the interventional suite,” said
Tom Livingston, President and CEO. “We are investing intentionally in leadership and
execution to accelerate adoption of our radiation safety platform. Rob’s experience scaling
high-performing sales organizations in intense growth environments makes him the right
leader for this next phase.”
“Serving on the Board gave me a front-row seat to the strength of Rampart’s team and the
momentum building in the market,” said Williamson. “This is a company with a clear
mission and a diFerentiated platform. I’m energized to lead the sales organization and help
bring this solution to more healthcare teams across the country.”
Interventional specialists face some of the highest occupational radiation exposure levels
in medicine.¹ Traditional 20–30-pound lead aprons, long used for protection, are
associated with significant orthopedic injury.² ³
Rampart’s portfolio of radiation safety solutions delivers total body, total team protection
for everyone in the interventional suite. Utilizing completely lead-free radiation-attenuating
materials with 1mm lead equivalency, Rampart provides expansive shielding without
compromising workflow. The company owns and manufactures its proprietary ClearShield
attenuation material, maintaining supply chain control and enabling fully lead-free product
solutions.
Rampart Systems are deployed in leading academic institutions as well as U.S. healthcare
systems and distributed globally.
Founded in 2018, Rampart develops radiation-attenuating solutions designed to protect
the entire procedural team and support safer, more sustainable careers in the
interventional suite.
Learn more at www.rampart.com.
References:
1. Zakeri F, Hirobe T, Akbari K. Biological effects of low-dose radiation exposure on
interventional cardiologists.Occup Med (Lond). 2010;60(6):464-469.
2. Orme NM, Rihal CS, Gulati R, et al. Occupational health hazards of working in the
interventional laboratory. J Am Coll Cardiol. 2015;65:820-826.
3. Klein LW, et al. Occupational health hazards of interventional cardiologists. Catheter
Cardiovasc Interv. 2015;86(5):913-924.
###
ABOUT RAMPART
Rampart is a Birmingham, Alabama–based medical device company redefining
interventional radiation safety through rigorous clinical evidence. Supported by two
randomized controlled trials and more than 1,700 real-world procedures, Rampart’s
solutions deliver greater than 99% scatter radiation reduction and are proven to be up to
20x more eFective than lead aprons and traditional shields.
Designed with zero pounds of wearable burden and engineered so that it adds no weight to
the clinician or the procedure table, Rampart eliminates the orthopedic strain long
associated with wearing lead aprons while preserving full procedural freedom. All Rampart
radiation protection solutions are manufactured using lead-free materials, supporting a
more sustainable approach to radiation safety while delivering eFective scatter-blocking
protection without traditional lead-based shielding. Available nationwide and through
global distribution partnerships, Rampart provides total body, total team protection for
those who work in the interventional suite —empowering providers to confidently Shed the
Lead®.
###
ABOUT RAMPART
Rampart is a Birmingham, Alabama–based medical device company redefining interventional radiation
safety through rigorous clinical evidence. Supported by two randomized controlled trials and more
than 1,700 real-world procedures, Rampart’s solutions deliver greater than 99% scatter radiation
reduction and are proven to be up to 20x more eFective than lead aprons and traditional shields.
Designed with zero pounds of wearable burden and engineered so that it adds no weight to the
clinician or the procedure table, Rampart eliminates the orthopedic strain long associated with
wearing lead aprons while preserving full procedural freedom. All Rampart radiation protection
solutions are manufactured using lead-free materials, supporting a
more sustainable approach to radiation safety while delivering eFective scatter-blocking protection
without traditional lead-based shielding. Available nationwide and through global distribution
partnerships, Rampart provides total body, total team protection for those who work in the
interventional suite —empowering providers to confidently Shed the
Lead®.
